MARKET

NUVA

NUVA

NuVasive
NASDAQ

Real-time Quotes | Nasdaq Last Sale

63.16
+0.32
+0.51%
After Hours: 63.16 0 0.00% 16:56 09/24 EDT
OPEN
62.73
PREV CLOSE
62.84
HIGH
63.74
LOW
62.34
VOLUME
790.60K
TURNOVER
--
52 WEEK HIGH
72.61
52 WEEK LOW
43.11
MARKET CAP
3.26B
P/E (TTM)
1825.43
1D
5D
1M
3M
1Y
5Y
JPMorgan Small Cap Sustainable Leaders Fund Buys Arena Pharmaceuticals Inc, Unifi Inc, ...
GuruFocus News · 2d ago
5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space
Zacks.com · 2d ago
NuVasive Opens East Coast Experience Center in New York Metropolitan Area
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the opening of its East Coast Experience Center in the New York me...
PR Newswire · 2d ago
NuVasive Partners with Scoliosis Research Society in Ongoing Double Diamond Sponsorship
/PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its long-standing partnership wit...
PR Newswire - PRF · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 09/13 12:10
BRIEF-Nuvasive Expects Net Sales In Q3 To Be Lower Sequentially From Q2
reuters.com · 09/13 11:54
NuVasive Simplify Cervical Disc Data Published In International Journal Of Spine Surgery
NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify®
Benzinga · 09/09 11:11
Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia to the Board of Directors
Kadia joins Board as an Independent Director who brings significant expertise in commercializing disruptive life science technologiesEMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biolog...
GlobeNewswire · 09/09 10:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NUVA. Analyze the recent business situations of NuVasive through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NUVA stock price target is 74.07 with a high estimate of 90.00 and a low estimate of 56.00.
EPS
Institutional Holdings
Institutions: 424
Institutional Holdings: 58.43M
% Owned: 113.09%
Shares Outstanding: 51.66M
TypeInstitutionsShares
Increased
87
3.69M
New
34
465.45K
Decreased
86
3.73M
Sold Out
32
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Wolterman
Chief Executive Officer/Director
J. Christopher Barry
Chief Financial Officer/Executive Vice President
Matthew Harbaugh
Chief Human Resource Officer/Senior Vice President
Lucas Vitale
Executive Vice President
Brent Boucher
Executive Vice President
Massimo Calafiore
Senior Vice President/General Counsel/Secretary
Nathaniel Sisitsky
Senior Vice President
Dale Wolf
Vice President/Director of Investor Relations
Juliet Cunningham
Independent Director
Vickie Capps
Independent Director
John DeFord
Independent Director
Robert Friel
Independent Director
R. Scott Huennekens
Independent Director
Siddhartha Kadia
Independent Director
Leslie Norwalk
Independent Director
Amy Raimundo
Independent Director
Donald Rosenberg
No Data
About NUVA
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Webull offers kinds of NuVasive, Inc. stock information, including NASDAQ:NUVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NUVA stock methods without spending real money on the virtual paper trading platform.